247 results about "Intra ocular pressure" patented technology

The invention is characterized in that it comprises a truncated contact lens (1), whose truncation plane is parallel to the base of said contact lens, and a polymeric nanocomposite material (2) centrally disposed and attached to the perimeter of the truncated area, said material being sensitive to pressure changes, biocompatible and transparent, and including contact electrodes (3), and in that it also comprises means for transmitting IOP measurement data to an external system. The invention also relates to a method for measuring IOP using said lens comprising: i) placing said sensor contact lens in the eye to determine its intraocular pressure; ii) providing a direct current value between external electrodes; iii) ΔV measurement between internal electrodes; and iv) identifying whether the value obtained is outside the linear response, expressed in changes of resistivity, of the polymeric nanocomposite material. The invention also relates to a telemetry system comprising said lens.

A surgical technique wherein an indwelling shunt is placed in the eye of a patient having glaucoma. The shunt diverts aqueous humor from a deep scleral lake or directly from the anterior chamber to the suprachoroidal space from which it is removed by blood flowing in the choroidal and uveal tissues. This decreases the intra-ocular pressure. The indwelling shunt maintains the area of exposure of aqueous humor with the uvea by physically preventing scarring of the surrounding tissues. The method utilizes the 25 mm Hg driving force of the protein colloidal osmotic pressure of the blood to maximize the flow.

Surgical method and apparatus for presbyopia correction and glaucoma by laser removal a portion of the sclera and / or ciliary tissue are disclosed. The disclosed preferred embodiments of the system consists of a beam spot controller, an articulated arm and an attached end-piece. The basic laser beam includes UV laser having wavelength ranges of (0.19-0.36) microns, generated from UV excimer lasers of ArF, XeCl or solid state lasers of Nd:YLF, Nd:YAG, Ti:sapphire with harmonic generation using nonlinear crystals. Presbyopia is treated by ablation of the treated surface tissue in predetermined patterns outside the limbus to increase the accommodation of the eye. Glaucoma is treated by decreasing of intra ocular pressure of the laser surgery.

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+ / K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

A silicon monolithic miniature intra-ocular pressure sensing probe utilizes pressure sensing piezoresistors attached to a silicon pressure sensing membrane which is directly exposed to the irrigating fluid used during an eye operation, for example. From a silicon fabrication point of view, this is a micro electromechanical (MEM) device and the integration of the piezoresistive pressure sensor directly into the cannula which is inserted into the eye is partially made possible by providing p++ etch stops to gain access for electrical connection to the piezoresistive elements arranged in a Wheatstone bridge configuration. The silicon sensing membrane forms a smooth surface to avoid turbulence and is close to the eye to minimize error.

The object of the present invention is to discover a combination of preventive or therapeutic drugs for glaucoma or ocular hypertension, which is useful as a preventive or therapeutic agent for glaucoma or ocular hypertension. By combining isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate with other preventive or therapeutic drug for glaucoma or ocular hypertension, their intraocular pressure lowering effects are complemented and / or enhanced each other. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug.

The object of the present invention is to discover a combination of preventive or therapeutic drugs for glaucoma or ocular hypertension, which is useful as a preventive or therapeutic agent for glaucoma or ocular hypertension. By combining isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate with tafluprost, their intraocular pressure lowering effects are complemented and / or enhanced each other. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug.

The present invention provides ocular implants adapted to reside in Schlemm's canal for reducing intraocular pressure of an eye and methods for using the same. In some embodiments the ocular implants comprise a thin rod adapted and configured to extend in a curved volume in Schlemm's canal. The thin rod comprises a plurality of wave-shaped segments such that a sufficient number and amount of wave-shaped segments extend to the inner wall of the trabecular meshwork and to the outer wall of Schlemm's canal thereby keeping Schlemm's canal open.

A viscoelastic medium is useful for the manufacture of a medicament, such as a medical device, for treatment of increased intraocular pressure in the eye of a human or animal. The medicament is administerable into at least one sclerally penetrating fistula of the eye such that the fistula is filled with the medicament. The medium is also useful in a method of treating increased intraocular pressure in the eye of a human or an animal in need thereof, comprising the step of injecting the viscoelastic medium into at least one sclerally penetrating fistula in the eye such that the fistula is filled with the medium.

Methods and devices for monitoring intra-ocular pressure of a patient using a miniature implantable sensor device are provided herein. Methods include obtaining multiple pressure measurements each day during an increment of an extended monitoring period according to a sampling program and wirelessly transmitting stored measurement data and wirelessly charging the device. Measurements and data process is performed with low power requirements such that sampling can be performed hourly for at least one week using energy stored on the miniature device and measurement data can be transmitted and the device charged rapidly when an external portable data acquisition / charging device is held in proximity to the device. In one aspect, methods include switching between differing use modes and powering the sampling device with a high impedance battery by switching between a supercapacitor and the battery with a microcontroller to perform impedance conversion.

Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I)and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

The invention relates to the use of Abnormal Cannabidiols in a combination with a drug selected from the group consisting of β-blockers, adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, chlolinesterase inhibitors, glutamate antagonists, prostamides and prostaglandins and the like, or pharmaceutically acceptable salts or prodrugs thereof as potent ocular hypotensives. Said combinations are particularly suitable for the management of glaucoma. In particular said Abnoral Cannibidiols are represented by formula I or formula II or formula III

A method and device for shunting fluid from high pressure volumes to low pressure volumes to treat various medical problems caused by an imbalance or malfunction of the regulation of flow between these volumes. Typical problems where the method and device are employed include the treatment of incontinence, treatment of hydrocephalus, treatment of elevated intra-cranial pressure, treatment of elevated intra-ocular pressure and the like. The controlled release of fluid from the high pressure volume is accomplished by inserting a sponge using an insertion device such as an endoscope. The sponge retains and releases fluid in response to a pressure differential between the high and lower pressure volumes. The sponge material may be natural or synthetic and sponges with different porosity and fluid retention are provided to achieve desired flow characteristics. The sponges can be provided with different shapes to allow it to conform to the anatomy and may have additional or integral modules that attach it to the anatomical structures.

A pharmaceutical composition for preventing or treating visual function disorders caused by ocular circulatory disorders (for example, ocular hypertension and glaucoma) and visual function disorders based on ciliary tension (for example, myopia) whose active component is a vasopressin antagonist.

A pharmaceutically acceptable carrier for ophthalmic compositions useful in treating or alleviating the symptoms of dry eye syndrome, elevated intra-ocular pressure, age-related maculopathy or age-related macular degeneration.

An intra scleral implant and method of implantation for use in the treatment of intraocular pressure and presbyopia. The implant features a body portion and protrusions from the body portion to anchor the device in a cavity formed in the scleral wall of the eye. Optionally a drug delivery function is provided to allow long term communication of drugs to tissue surrounding the implant.

The present invention relates to an ophthalmic aqueous composition containing PGF2α analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2α analogues in an aqueous composition.

A Device which enables a person to see for himself changes in Intra Ocular Pressure when he looks at his eye in the Mirror, in the routine course of everyday, as every one likes to see his Own face and eyes in the Mirror everyday. The device being Tiny and inserted surgically with minimum incision between Iris and Cornea, enables early indication of IOP in people with high risk of Glaucoma due to high blood pressure and genetic reasons and old age, the early indication enabling timely treatment before retinal damage. The device works on pattern changes due to pressure change which is compared with fixed background pattern and changes in spacing between lines of Diffraction grating and Hologram leading to colour changes due to interference effect of light. Mirror with an area of concave surface and Magnifying device along with comparison Chart enables proper monitoring of drug efficacy.

The invention concerns a system of measuring ocular pressure, consisting of at least one implant (30) including a pressure sensor (33) and an electronic circuit (32), implanted in the cornea of an eye and an antenna (31) connected to the said circuit and implanted in the sub-conjunctival space; and a unit (50) for processing the representative values of the pressure, received by a radio-frequency link from the said electronic circuit (30).

An contact tonometer for sensing intra-ocular pressure (IOP) including a micro-electro-mechanical system (MEMS) device forming a transducer / sensor at or in contact with a contact end of the tonometer where the cornea is contacted and electronics receiving an electrical signal from the transducer and processing the signal to produce a display indicative of intra-ocular pressure.

The invention provides particular uridine di- and tri-phosphate derivatives, and pharmaceutical compositions thereof. These compounds are useful for treatment of diseases, disorders and conditions modulated by P2Y6 receptors, and particularly for lowering intraocular pressure and thereby treating ocular hypertension and / or glaucoma.

The invention provides a device and method for analyzing the biomechanical property of cornea based on OCT three-dimensional imaging. The device comprises an OCT system, a master control machine, a cornea fixer, an intra-ocular pressure controller and a pressure sensor, wherein the OCT system comprises a low-coherence source, an optical fiber coupler, a reference arm, a spectrograph, an optical collimator, a two-dimensional scanning galvanometer and a syntaxis lens. According to the device and method, interference spectrum information is transmitted to the master control machine by virtue of the spectrograph, so that the cornea structure information is acquired after the master control machine is subjected to spectrum analysis, and parameters of the biomechanical property of cornea is acquired for disease diagnosis and researches.

The invention discloses a system capable of measuring intra-ocular pressure and assessing cornea viscoelasticity at the same time. The system comprises a shell with an opening. A flexible thin film is arranged on the opening side of the shell. A containing cavity is formed by the shell and the flexible thin film. The containing cavity is filled with fluid. A pressure module is arranged on the side wall of the shell. The pressure module is used for monitoring the pressure of fluid and adjusting the pressure in the containing cavity. An ultrasonic module is arranged on the top of the shell. By the adoption of the system and method for measuring intra-ocular pressure and assessing cornea viscoelasticity, non-invasive measurement of intra-ocular pressure in vivo and assessment of the mechanical property of the cornea can be achieved, the accuracy and the reliability of measurement of intra-ocular pressure can be effectively improved, the index for describing the mechanical property of the cornea is provided, the individual difference of the mechanical property of the cornea is reflected, reference is provided for clinical diagnosis and treatment, the defects that the abnormal mechanical property of the cornea influences the measurement of the intra-ocular pressure, and the difference of the intra-ocular pressure influences the biomechanical quantitative evaluation of the cornea are overcome.

A porous nanometer carbon-polyvinyl alcohol hydrogel artificial cornea, which is used for patients of cornea diaphaneity descent and cornea blind caused by eye tissue diseases, consisting of an optical part and a supporting part, the optical part being made from transparent polyvinyl alcohol hydrogel, and the supporting part being made from black nanometer carbon materials. The optical part is provided with an upper and a lower surface, the supporting part enwraps the optical part, combines tightly with human cornea tissues, and is embedded in the optical part. The materials of the optical part protrude on the top and the bottom and overtops the supporting part at the joint of the two parts, and forms a trapezoid right-angle structure. The invention overcomes the shortcomings of existing techniques, and is capable of watertightness engomphosis with host cornea, preventing infection, degrowth of corneal epitheliums, antagonizing intra-ocular pressure, and preventing the forming of the back fibrous membrane of cornea. The artificial cornea has advantages of tenderness, good elasticity, certain tensile strength, convenience in surgical operation, and maximum decrease of complicating diseases.

The invention relates to a spray, in particular to a rose spray for relieving eyestrain and a preparation method thereof. The rose spray mainly comprises the following components: rose extract, essential rose oil, trehalose, hydrogenated castor oil, pentanediol, dipotassium glycyrrhizinate, menthol, aseptic, sodium hyaluronate, propylene glycol, butanediol and water. The preparation method first uses propylene glycol and butanediol to dissolve sodium hyaluronate, in addition, pentanediol is added to dissolve menthol, hydrogenated castor oil is added to be uniformly mixed with essential rose oil, the three types of solutions are mixed and added with the rest components, and thereby the rose spray is obtained. When directly sprayed around the eyes, the rose spray disclosed by the invention can promote the microcirculation of the skin of the eyes, improve the blood flow of the blood vessels of the eyes and decrease intraocular pressure, thus achieving the effect of relieving eyestrain and eyesight fatigue; moreover, the rose spray also has excellent water-retaining property, and can reduce the muscular flaccidity of the eyes and tighten pouches, so the rose spray is an ocular anti-fatigue spray with a skin-care function.